BeiGene, Ltd. (ONC) Stock Analysis

BeiGene, Ltd. (ONC) is a publicly traded company in the HEALTHCARE sector. It trades at $274.69, carries a market capitalization of $29.02B, a price-to-earnings ratio of 63.28. This page summarizes the public market data, fundamentals, and frequently asked questions for ONC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $274.69
• Market Cap: $29.02B
• P/E Ratio: 63.28
• EPS: $4.42
• 52-Week High: $385.22
• 52-Week Low: $239.25

Market Sentiment

BeiGene, Ltd. currently has a Neutral sentiment score of 0.03.

About BeiGene, Ltd.

BeiGene, Ltd. (Ticker: ONC) is a pioneering global biotechnology company focused on advancing cancer treatment through innovative drug discovery and development. With a robust presence in key markets, including the United States, China, and Europe, BeiGene is dedicated to addressing critical unmet needs in oncology. The company's extensive pipeline of proprietary therapies, complemented by strategic collaborations, underscores its commitment to precision medicine and enhancing patient outcome...

GNG Research Analysis

GNG Research scores BeiGene, Ltd. (ONC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ONC.

Frequently Asked Questions

Does ONC pay dividends?

BeiGene, Ltd. (ONC) does not currently pay a regular dividend.

What is ONC's P/E ratio?

BeiGene, Ltd. has a price-to-earnings (P/E) ratio of 63.28.

What is ONC's market cap?

BeiGene, Ltd. (ONC) has a market capitalization of $29.02B with a current stock price of $274.69.